

[18F]FDG-PET/CT in Pancreatic Cancer: Challenges and Advances

Daniel Juarez

December 12, 2024

1 Introduction

Pancreatic cancer is a type of cancer that starts to spread out from the pancreas. The pancreas is situated behind the stomach and its functions include secreting of digestion enzymes and regulating blood sugar. What makes pancreatic cancer really serious is its *poor prognosis* this means that compared to other cancers this one is harder to treat successfully, harder to detect or prevent from growing.

This type of cancer is one of the most challenging in the field of oncology, it has a notably high mortality rate and low survival rates. In the US, pancreatic cancer is currently the 10th most commonly diagnosed cancer, with an estimated 66,440 new cases anticipated in 2024, accounting for 3.3% of all new cancer cases [1]. The incidence rate is about 13.5 per 100,000 men and women, with annual increases of about 1% since the early 2000s. And sadly, it is responsible for 8.5% of all cancer-related deaths, with an estimated 51,750 deaths expected in 2024 [1].

This similar scenario is observed across the world, for example in Mexico it ranks 12th in incidence, and 7th in mortality [2]. In China incidence ranks 8th. Overall, Pancreatic cancer is the fifth most common cause of cancer-related deaths in South Korea, and the fourth leading cause of cancer-related deaths in the US and Europe. [3]

Moreover, pancreatic ductal adenocarcinoma (PDAC), one of the most lethal human cancers that conforms 85% of pancreatic cancers, is estimated to be the second leading cause of cancer-related deaths by 2030. [4][5].

This is a general concern for health professionals and it reflects the limited or "slow" advances in diagnosis and treatment for this malignancy.

Given this statistics, it is crucial for us to quickly identify and treat this type of cancer. This can be quite challenging as it has an aggressive nature and

asymptomatic progression. Usually this malignancy doesn't manifest and this leads to diagnoses in more advanced stages and by then surgery is rarely viable [6].

There specific reasons why PDAC early detection is challenging has its root in different factors. On the clinical side of things, the initial stages of pancreatic cancer often go unnoticed as symptoms are minimal and non-specific. This early stage end quickly, the rapid progression and aggressive nature of the disease contributes to the complexity, by this time symptoms are noticeable but may be too late. Additionally, the deep location in the anatomy of the pancreas complicates physical examination.

On the technical part, unlike other malignancies, pancreatic cancer lacks a standardized and reliable screening protocol for the general population, reducing the likelihood of early intervention. Furthermore, existing imaging modalities often fail to detect smaller lesions or early-stage pancreatic cancer [6]. It is worth pointing out that even surveillance with available techniques is sometimes not recommended if the patient has not developed any symptoms.

Given these diagnostic limitations, there is an increasing demand for imaging solutions can appropriately stage the disease and detect it early in order to improve patient outcomes. Recent literature emphasizes the need for screening programs for asymptomatic, high-risk individuals with non-invasive precursor lesions, rather than those in advanced stages [5].

Now, how can we detect this malignancy given all this challenges? Medical imaging is particularly useful in this case, it is able to provide information for treatment planning and assessing resectability. Current guidelines, including those by the National Comprehensive Cancer Network (NCCN) and the European Society for Medical Oncology (ESMO), point out that computed tomography (CT) is the

primary imaging modality for assessing pancreatic cancer [3]. However, emerging modalities such as endoscopic ultrasound (EUS) and magnetic resonance imaging (MRI) are quickly becoming more common as supplementary techniques for early-stage evaluation. There is data that compares these modalities in terms of strength, weaknesses and performance that suggests that a hybrid approach like PET/CT will allow for the detection of increased glucose metabolism, offering insights beyond structural abnormalities. [7]

1.1 FDG PET/CT

A promising modality for cancer diagnosis and staging is Positron emission tomography/computed tomography (PET/CT). While PET scans are able to capture cellular metabolic changes, CT provides anatomical mapping, this hybrid approach of techniques enables a complete assessment of the disease. Recent studies explore the main advantages and procedures involved using PET/CT with 18-fluorodeoxyglucose ([18F]FDG) a tracer to assess pancreatic cancer. They highlight that the unique advantage of [18F]FDG-PET/CT is in its sensitivity to the metabolic activity of cancer cells, providing valuable insights into both the presence of tumors and their potential aggressiveness [8].

Because of the asymptomatic and aggressive nature of PDAC, giving a clear diagnostic is challenging even now with imaging modalities. The advancements in this modalities like [18F]FDG-PET/CT, are very promising improving early detection rates and treatment outcomes. This paper will explore the current applications of [18F]FDG-PET/CT in pancreatic cancer diagnosis and staging, with a focus on overcoming diagnostic limitations and enhancing the accuracy of early detection.

2 The Nature of Pancreatic Cancer

The pancreas is an accessory organ of the digestive system, just like the liver, the gallbladder and salivary glands. The pancreas is located in the upper abdomen retroperitoneally, that is behind the peritoneum, the tissue that lines the abdominal wall and covers most of the abdominal organs [9], as shown in figure 1.




Figure 1: The position of the pancreas in the body and its surrounding organs. Source: [10].

It has 3 main parts, the head lies within the C-shaped curve of the duodenum and the body and tail extend across the midline towards the spleen. [11] The division of the pancreas into three main parts (head, body, and tail) helps understand its vascular anatomy too. This is important since radiotracers find their target through this pathways.

The pancreas receives blood from multiple sources, for example the head gets blood from the superior and inferior pancreaticoduodenal arteries and then drains via the superior mesenteric vein. The suppliers of blood for the body and tail are branches of the splenic artery and drains through the splenic vein. [9, 11]

Another relevant part of the pancreas are its ductal system, the main pancreatic duct (Wirsung duct) runs the length of the pancreas and joins with the common bile duct to form the hepatopancreatic ampulla (ampulla of Vater).[11] Depicted in figure 2 as pancreatic duct and Orifice of common bile-duct.

Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive malignancy and is characterized by rapid progression. It has distinct biological and structural features, the relevant ones for imaging it are two, altered glucose metabolism (metabolic re-programming) and a dense fibrotic tumor microenvironment. These characteristics create significant challenges for traditional imaging modalities, thus medical physicists and physicians require advanced techniques like PET/CT for accurate diagnosis.




Figure 2: The pancreas and its ducts, arteries, and veins. Image by Henry Vandyke Carter, Public Domain, via Wikimedia Commons. Source: [12].

The disease can manifest anywhere in the pancreas but most PDACs (60–70%) arise from the head. While 20–25% of PDACs originate in the body or tail of the pancreas. Tumors in the pancreatic head tend to be diagnosed earlier due to their proximity to the common bile duct [13].

PDAC arises from cells of the pancreatic duct or ductules [13]. The tumor is often surrounded by a prominent desmoplastic stroma, a dense connective tissue growth, which contributes to its aggressive behavior [14]. Because of this, vascular invasion is common, occurring in about 65% of cases, and is associated with poorer prognosis [15]. Also, as illustrated by figures 1 & 2 the pancreas has very important surrounding structures meaning that PDAC can directly extend into nearby organs like the spleen, adrenals, stomach, and transverse colon. [16]

PDAC tumors have metabolic alterations, explained by the Warburg effect.[17] The Warburg effect occurs when cells change to a sugar-based energy pathway, over oxygen-based ATP production, even in oxygen-rich conditions. ATP, the molecule cells use for energy, is normally generated through oxygen-driven processes, but glycolysis allows tumor cells to grow rapidly. This shift is driven by genetic mutations associated with cancer, such as KRAS, which increase the production of glucose transport proteins (GLUT1) and processing enzymes (hexokinase-2), this allows for cell proliferation and growth. [6, 8].

PET/CT imaging for pancreatic lesions must reveal several key features to aid in diagnosis. First,

from PET images elevated FDG uptake compared to benign lesions is expected, as cancer cells typically exhibit increased glucose metabolism. This scanner can detect the accumulated hyperglycolytic tumor cells, via the radiotracer [18F]FDG, a glucose analog, meaning it can detect PDAC lesions, with sensitivity rates of 89–91% and specificity rates of 70–72% in clinical applications [8].

The scan needs to provide information on the size and location of the lesion, as well as any presence of cystic necrosis, since is more common in PDAC (59.6% of cases). Some other important information that can be extracted from a PET/CT scan is the spread of the disease, via vascular invasion or metastases on liver or peritoneal [18].

Usually, on a conventional PET/CT protocol, a CT scan is performed without any alteration. From this scan, data on the attenuation coefficients are obtained and it allows to correct PET images later. It also provides anatomical localisation, so the high FDG part can be identified [19]. Recent studies explore the newest technology that is used to diagnose PDAC, that include MRI with Diffusion weight imaging (DWI) and Dynamic Contrast Enhance (DCE), elastography and nanoparticles. [5]

A main challenge for diagnostics from these images is differentiating PDAC from pancreatitis. The tumor size in mass-forming chronic pancreatitis (MFCP) tends to be larger (mean size 4.00 ± 0.47 cm) compared to PDAC (mean size 3.42 ± 0.75 cm) [20]. But those values are pretty close to each other pointing that diagnosing out of only tumor size is nearly impossible.

Thankfully, we got some other data to help distinguish between the two. An example is that, PET/CT can better detect vascular invasion, which is more common in PDAC (53.2%) than in MFCP (23.8%). And other factors like cystic necrosis and atrophy can also play a role, since these factors are more frequently observed in PDAC than in MFCP [20].

A key factor is that PDAC typically shows higher FDG uptake (higher SUVmax) compared to MFCP due to increased glucose metabolism in cancer cells [20, 8]. However, even with this metrics diagnostics is quite challenging, as we will explore in a later section on this paper.

Thick fibrous tissue (desmoplastic stroma) surrounds cells in organs, is made up of fibroblast cells and extracellular proteins like collagen. In normal

tissues, it provides structure and helps supply nutrients to healthy cells. However, in cancer the stroma becomes abnormally dense and fibrotic. This is called desmoplasia and helps the tumor grow and evade immune attacks, for imaging purposes, this thick tissue also makes it harder for CT and MRI to clearly identify the tumor's boundaries [3].

Additionally, hypoxic regions within the tumor alter glucose metabolism, causing variability in [18F]FDG uptake. This will be discussed in depth later in this document. Making imaging more complicated, inflammatory conditions, such as pancreatitis can produce lesions with overlapping metabolic signatures on PET/CT. As noted by Pu, Y. [8], "both autoimmune pancreatitis and pancreatic cancer appear as metabolic abnormalities and increased FDG accumulation".

The challenges presented above highlight the need of development on advanced imaging modalities to ensure accurate diagnosis and staging of these types of cancer. PET/CT combines the sensitivity of metabolic imaging with the spatial resolution of CT, and has emerged as a strong candidate for precise tumor localization and characterization.

Recent studies agree on this and are doing research on the topic. Stating that "The combination of PET and CT can determine the metabolic capacity and anatomical position of pancreatic tumor cells in the body and can accurately diagnose the patient's condition and tumor location" [8]. Other research shows interest in different modalities, such as PET/MR and the use of other radiotracers for targeting hypoxic or stromal regions. But they all agree that development is needed. This development hold promise for enhancement in diagnostic specificity and sensitivity, although they require validation in clinical settings [5].

For comparative analysis on PET/MR and PET/CT in therapeutic applications, see also [21]. Where an exploration on what MR offers is included. The main advantages that MRI can add are reduced dose when compared with PET/CT and as an standalone modality, the DWI & DCE allows for additional functional information on the ducts and veins of the accessory digestive system organs to be obtained.

2.1 The Importance of Early Detection

Patient outcomes depend entirely on the capacity to early detect pancreatic ductal adenocarci-

noma (PDAC). Despite advancements in therapeutic strategies, over 80% of PDAC patients have locally advanced or metastatic disease at the time of diagnosis, at this stage the curative options are limited. Early-stage detection allows for timely surgical resection, the only potentially curative treatment that improves survival rates [5].

Because of the asymptomatic progression and aggressive nature of PDAC its early detection is extraordinarily difficult. Current technology and traditional imaging techniques, like CT and MRI, offer insights when assessing this disease but are limited by their ability to identify small lesions or distinguish benign from malignant tumors early on. These cases are well illustrated in resource-limited settings, if PET/CT is scarce this challenge becomes even more daunting. For instance, in Mexico PET scanners are centralized in major cities and early detection relies heavily on less sensitive modalities like CT or X-ray, which are often insufficient for timely diagnosis.

The reality of this worldwide problem is showcased in many real-world cases, a personal example is that of my grandmother, whose diagnosis of PDAC came only after her passing, despite months of observation and testing.

Better imaging modalities, such as [18F]FDG-PET/CT, can address some of these issues. The combination of functional and anatomical imaging improves sensitivity and specificity for early lesions, thus enables metabolic changes to be detected before morphological alterations appear [8]. However, access to these technologies remains uneven globally. As of 2021, Mexico had only 26 PET scanners for its entire population, around 126 Million people [22], concentrated in a few hospitals in major cities [23]. There is a need for international collaboration to expand access to advanced imaging technologies, both through equipment and expertise.

Another proposed solution to these problems is the addition of surveillance for high-risk groups, with population-specific screening programs targeted to individuals with familial predisposition, cystic lesions, or diabetes mellitus in order to identify precursor lesions or early-stage PDAC [5].

Furthermore, these programs are limited in settings where resources are lacking. Following my personal story, that of my grandmother, who was a high-risk patient with diabetes and a delayed diagnosis, exemplifies the need for accessible and standardized surveillance protocols. The value of those programs

not only relies on saving lives but on valuable insights into familial risk factors, which is an area of interest for researchers and patients alike.

When PDAC is diagnosed at a localized stage, surgical resection is more likely to be feasible. Advanced imaging techniques like [18F]FDG-PET/CT

offer the potential to identify tumors earlier. Expanding access to these technologies and implementing population-specific screening programs puts the world in the right direction to address this global health challenge and improve outcomes for future patients.

3 Overview of Imaging and [18F]FDG Tracer

3.1 Technical Principles of PET/CT

Positron Emission Tomography (PET) is a functional imaging modality that uses positron-emitting radionuclides to map metabolic activity in tissues. As standalone imaging modality it lacks of anatomic structure localization, for that it is integrated with Computed Tomography (CT). CT contribution is huge, it provides attenuation correction, electron density, and anatomical localization. This way, PET/CT provides both functional and structural data in a single imaging session and with it a valuable approach in planning and diagnosing. With the use of PET annihilation gamma rays and CT high resolution it is possible to find accurately the localization of metabolic abnormalities [24]. By taking the best of both modalities it is ensured that all metabolic information is properly contextualized on the anatomy reducing errors on registration state compared to standalone systems [25].

The now well established Time-of-flight (TOF) technology allows to get precise timing of gamma-ray detection to improve spatial resolution and reduce noise. As it solves the problem of measure the exact site of annihilation it enhances signal-to-noise ratio (SNR), particularly for larger patients. [26] PET technology has advanced a lot in recent years with detection enhancement, such as the adoption of Silicon Photomultiplier Arrays (SiPM) replacing older photomultiplier tubes (PMTs) augment resolution and sensitivity [27]. And with it the regulations and quality assessments ensure that metrics like Standardized Uptake Value (SUV) are reliable.[24].

Additionally, there is another important factor related to PET scanners, as PET imaging requires administration of radiopharmaceuticals. This administration must be performed with accuracy as any error in this step, can lead to uneven tracer distribution. The next section will explore more about the particular radiotracer [18F]FDG. Sunderland et al. demonstrated that injection infiltration occurs in less than 0.4% of cases. Moreover, computational modeling suggests that even when infiltration occurs, its impact on dosimetry and image quality is negligible [28].

3.2 Mechanism of [18F]FDG Uptake

Fluorine-18 Fluorodeoxyglucose or [18F]FDG is a glucose analog labeled with the positron-emitting isotope fluorine-18. After intravenous injection, FDG is transported into cells by glucose transporters like GLUT1 and the enzyme hexokinase adds a phosphate group (phosphorylase) to it. Since this is now a different molecule from glucose cells cannot longer proceed in the glycolysis process, and the molecule gets trapped in cells with high glucose metabolism, such as tumor cells [24, 29].

This characteristic of the cancer cell is what allows for PET to visualize regions of hyperglycolysis. For example, as shown in Figure 3, PET images A) show regions of increased metabolic activity in the pancreatic head, in B) CT images provide anatomical context. The fused PET/CT image C) integrates these modalities, and allows for precise localization of pancreatic tumors. Then oncogenic mutations like KRAS drive this process by upregulating GLUT1 and hexokinase-2, further amplifying glucose uptake [30]. But this is not the only reason FDG accumulation can increase, this behavior is also present in inflammation and benign conditions, such as autoimmune pancreatitis [29]. Different radiotracers may shine some light into the problems faced right now and with them new advancements in tracer specificity and imaging protocols emerge.




Figure 3: 18F-FDG PET/CT imaging integrating metabolic and anatomical data: (A) PET image, (B) non-enhanced CT image, (C) fused PET and CT images, demonstrating pancreatic head cancer detection [8].

4 Applications in Staging and Diagnosis

With the complementary strengths of PET and CT scanners assessing tumor margins and guiding surgical interventions is possible. In the case for staging and diagnosing PDAC, PET/CT achieves sensitivity rates of 89–91% and specificity rates of 70–72% in detecting PDAC lesions [24].

Key applications include:

- **Tumor Localization and Metastases Detection:** PET/CT excels in identifying primary tumors and distant metastases by FDG concentrated regions lighting up. Zhang et al. demonstrated its utility in detecting rare metastatic sites, such as cutaneous and muscle involvement[31].
- **Lymph Node Evaluation:** In cancer, lymph nodes often act as early sites for metastasis. PET/CT is a great tool to assess lymph node involvement. When FDG concentrates it shows increased glucose metabolism due to cancer activity. This is unique information from PET since lymph nodes may appear normal in size on CT but are metabolically active. Accurate identification of these cancerous nodes improves staging precision, which is critical for planning surgeries, such as lymphadenectomy (removal of affected nodes), and for deciding if curative treatments are feasible [24].
- **Differentiating Lesions:** Since FDG uptake is non-specific, combining metabolic imaging

with clinical markers (e.g., IgG4 levels) can help distinguish autoimmune pancreatitis from PDAC [29].

Another one of the emerging technologies is the Total Body PET/CT systems. These systems seek to enable whole-body imaging in a single scan, hopefully with enhanced resolution and reduced scanning time [27]. This is a valuable innovation for detecting micrometastases and monitoring therapeutic responses.

PET/CT can be of great help during the different parts of treatment, from diagnosis, staging, to management of pancreatic cancer. In order to exemplify its applications three clinical cases are introduced:

- **Case 1 - Zheng et al.:** A 67-year-old male with suspected pancreatic cancer presented, in 2018, a metabolic active lesion was identified using a PET/CT scanner. This lesion is located in the head of pancreas and had hinted overlap of metabolic signatures typical of both malignancy and autoimmune pancreatitis[29].
- **Case 2 - Zhang et al.:** In 2023 case, a 64-year-old male with confirmed pancreatic adenocarcinoma and treated with radical resection 6 years earlier presented rare metastatic sites and was reevaluated[31].
- **Case 3 - Deng et al.:** Study in 2021 that compared FDG with 68Ga-FAPI, Gallium-68-labeled Fibroblast Activation Protein In-

hibitor, in a 58-year-old female with pancreatic cancer and liver metastases. DG-PET/CT identified hypermetabolic liver lesions, but 68Ga-FAPI demonstrated superior sensitivity in delineating hypodense metastases[30].

These cases together exemplify applications in the diagnosis and staging of pancreatic cancer of this imaging modality.

4.1 Tumor Localization and Metabolic Assessment

Metabolic Imaging in Practice: As stated before the value of FDG-PET resides on its ability to visualize regions of increased glucose metabolism, even in lesions not that well defined morphologically. A case application is the results of Deng et al. where FDG-PET/CT effectively detects hypermetabolic pancreatic tumors. But, new tracers like 68Ga-FAPI outperform FDG in identifying micrometastases, particularly in hypodense liver lesions [30].

Figure 4 illustrates the comparative uptake of 68Ga-FAPI and 18F-FDG in pancreatic cancer with liver metastases, the maximum density projection (MIP) image (A) shows increased FDG uptake in a pancreatic mass and mild uptake in the 10th rib, suggesting bone metastasis. Axial PET/CT images (B) highlight moderate uptake in the pancreatic head, while (C) reveals minimal bone destruction with mild metabolic activity in the 10th rib. Additionally, small hypodense nodules in the liver (D) were identified without significant FDG uptake, raising suspicion for liver metastases.

Quantitative Metrics in Action: The metric of choice is the Standardized Uptake Value (SUV), it measures FDG uptake in a lesion relative to a reference. The lower the SUV the better as it correlates to malignancy. By knowing this parameter it is possible to identify micrometastatic lesions, particularly in the liver. Deng et al. shows that 68Ga-FAPI has superior sensitivity highlighting it as a promising area for future research on radiotracers.[30]




Figure 4: Comparison of FDG-PET/CT metabolic activity. (Right) 18F-FDG PET/CT showing pancreatic mass and liver hypodense lesions with minimal uptake, highlighting its sensitivity in tumor and liver staging [30]. (Left) Enhanced metabolic activity in pancreatic lesions with high resolution, 68Ga-FAPI tracer's specificity in hypometabolic areas near liver[30].

4.2 Lymph Node Evaluation and Metastasis Detection

Unique Metastases: In case 2, PET/CT demonstrated its capacity to distinguish between muscle and cutaneous metastases from PDAC—locations rarely detected by conventional imaging. Without

PET/CT this would be possible to assess correctly

Figure 5, depicts a MIP image with two regions of elevated glucose metabolism (Upper abdomen and left lateral abdominal wall). An axial image of the anatomy shows near the surgery site that shows elevated metabolic activity, possibly indicating residual or recurrent cancer, or post-surgical inflamma-

tory changes. Then focused on the lateral it shows an hypodense structure seen in the muscle. This is the rare case of a metastatic deposit in the muscle. They highlight that Muscle metastases from pancreatic cancer are exceptionally rare, while cutaneous metastases occur in only 0.5–7.6% of cases, often at the umbilicus[31].

Sensitivity and Specificity: Zhang et al. found that FDG uptake reliably identifies malignancies, it may also highlight non-malignant inflammatory processes, necessitating careful interpretation and, when possible, the inclusion of additional clinical markers or advanced tracers.




Figure 5: Rare cutaneous and muscle metastases detected using FDG-PET/CT, illustrating its capability for identifying uncommon metastatic sites [31].

4.3 Treatment Planning and Monitoring

Guiding Therapy with PET/CT: In order to perform a surgical resection and radiation therapy the boundaries of the tumor must be carefully delineated. Zheng et al. were able to differentiate autoimmune pancreatitis from PDAC from this images, avoiding unnecessary or ineffective treatments [29].

Figure 6 showcases how PET/CT identifies metabolic distinctions that inform treatment in challenging cases where inflammatory and malignant lesions overlap. Additionally, post-treatment PET/CT imaging provides insights into metabolic response, that enables clinicians to adjust therapeutic regimens based on observed changes in FDG uptake.

Enhancing Planning with Alternative Tracers: As noted in Deng et al., the integration of new tracers like ^{68}Ga -FAPI offers improved sensitivity in hypoxic tumor regions. [30].




Figure 6: FDG-PET/CT imaging showing focal autoimmune pancreatitis mimicking pancreatic cancer. Note: the overlapping metabolic activity that challenges differentiation [29].

Section 4 demonstrated the utility that PET/CT provides to diagnosis, staging, and management of pancreatic cancer. These clinical cases are an example of the current technology and limitations that we have in terms of resolution and specificity, and accessibility. Addressing these limitations will lean this technology forward for better and precise treatment, innovations in radiotracer development and hybrid imaging modalities can certainly be the way forward.

5 Limitations and Future Directions

5.1 Current Limitations

FDG-PET/CT is widely used, but it has limitations. The major one is resolution, this makes detecting micrometastases really difficult. Another limitation is in the tracer it self, FDG lack the specificity in distinguishing inflammatory from malignant lesions and can lead to diagnostic uncertainty. Furthermore, accessibility remains an issue, as the high costs associated with FDG-PET/CT and its limited availability in certain regions hinder its adoption in resource-

5.2 Future Advancements

On the side of chemistry and nuclear physics, the development of radiotracers, such as ⁶⁸Ga-FAPI and ^[18F]FMISO, offers solutions to FDG's specificity challenges. These tracers target unique tumor characteristics, such as hypoxia and fibroblast activity [30]. Then on the resolution problem, technologies like PET/MR provide enhanced soft-tissue contrast and reduced radiation exposure, making them promising alternatives for pancreatic cancer imaging. Additionally, Total Body PET/CT systems promise comprehensive whole-body imaging in a sin-

gle scan, improving detection of micrometastases and overall efficiency.

6 Conclusion

FDG-PET/CT has is a great addition to the diagnostic approach for pancreatic cancer by combining anatomical and metabolic imaging. It has the

ability to localize tumors, stage disease, and guide therapy making it a solid choice for oncology assessment. However, addressing its limitations through advanced tracers and hybrid modalities is a priority. The ongoing evolution of PET/CT technology, coupled with global efforts to expand accessibility, will undoubtedly enhance its impact on pancreatic cancer outcomes.

References

- [1] American Cancer Society. 2024 cancer facts and figures, 2024. Accessed: 2024-11-09.
- [2] International Agency for Research on Cancer. Mexico fact sheet, 2024. Accessed: 2024-11-09.
- [3] H. Rhee and M. S. Park. The role of imaging in current treatment strategies for pancreatic adenocarcinoma. *Korean Journal of Radiology*, 22(1):23–40, 2021.
- [4] B. Li, M. S. Nelson, O. Savari, A. G. Loeffler, and K. W. Eliceiri. Differentiation of pancreatic ductal adenocarcinoma and chronic pancreatitis using graph neural networks on histopathology and collagen fiber features. *Journal of Pathology Informatics*, 13:100158, Nov 2022.
- [5] K. P. Farr, D. Moses, K. S. Haghghi, P. A. Phillips, C. M. Hillenbrand, and B. H. Chua. Imaging modalities for early detection of pancreatic cancer: Current state and future research opportunities. *Cancers*, 14(10):2539, 2022.
- [6] A. D. Singhi, E. J. Koay, S. T. Chari, and A. Maitra. Early detection of pancreatic cancer: Opportunities and challenges. *Gastroenterology*, 156(7):2024–2040, 2019.
- [7] Robert Christopher Subtirelu, Eric Michael Teichner, Yvonne Su, Omar Al-Daoud, Milan Patel, Shiv Patil, Milo Writer, Thomas Werner, Mona-Elisabeth Revheim, Poul Flemming Høilund-Carlsen, and Abass Alavi. Aging and cerebral glucose metabolism: 18F-fdg-pet/ct reveals distinct global and regional metabolic changes in healthy patients. *Life*, 13(10), 2023.
- [8] Y. Pu, C. Wang, S. Zhao, R. Xie, L. Zhao, K. Li, C. Yang, R. Zhang, Y. Tian, L. Tan, J. Li, S. Li, L. Chen, and H. Sun. The clinical application of [18F]-fdg pet/ct in pancreatic cancer: A narrative review. *Translational Cancer Research*, 10(7):3560–3575, 2021.
- [9] S. S. Talathi, R. Zimmerman, and M. Young. *Anatomy, Abdomen and Pelvis, Pancreas*. StatPearls Publishing, Treasure Island (FL), 2024 jan- edition, 2024. [Updated 2023 Apr 5].
- [10] Mount Sinai Health System. Pancreatic cancer. <https://www.mountsinai.org/health-library/diseases-conditions/pancreatic-cancer>, n.d. Image showing the position of the pancreas and its surrounding organs. Accessed 2024-12-12.
- [11] Kenhub Contributors. The pancreas. <https://www.kenhub.com/en/library/anatomy/the-pancreas>, n.d. Accessed 2024-12-12.
- [12] Henry Vandyke Carter. The pancreas, the pancreatic duct, orifice of common bile-duct and pancreatic duct, accessory pancreatic duct. Public Domain, via Wikimedia Commons, n.d. Image showing ducts, arteries, and veins of the pancreas. Source: talathi2023.
- [13] Alexander Stark and Guido Eibl. Pancreatic ductal adenocarcinoma. *Pancreapedia: Exocrine Pancreas Knowledge Base*, 2015.

- [14] L. Haeberle and I. Esposito. Pathology of pancreatic cancer. *Translational Gastroenterology and Hepatology*, 4:50, 2019.
- [15] S. M. Hong, M. Goggins, C. L. Wolfgang, R. D. Schulick, B. H. Edil, J. L. Cameron, A. Handra-Luca, J. M. Herman, and R. H. Hruban. Vascular invasion in infiltrating ductal adenocarcinoma of the pancreas can mimic pancreatic intraepithelial neoplasia: a histopathologic study of 209 cases. *The American Journal of Surgical Pathology*, 36(2):235–241, 2012.
- [16] Radiopaedia Contributors. Pancreatic ductal adenocarcinoma. <https://radiopaedia.org/articles/pancreatic-ductal-adenocarcinoma-4>, n.d. Accessed 2024-12-12.
- [17] N.G. Hammond, R.B. Cameron, and B. Faubert. Beyond glucose and warburg: finding the sweet spot in cancer metabolism models. *npj Metab Health Dis*, 2:11, 2024.
- [18] Ujas Parikh, Charles Marcus, Rutuparna Sarangi, Mehdi Taghipour, and Rathan M. Subramaniam. Fdg pet/ct in pancreatic and hepatobiliary carcinomas: Value to patient management and patient outcomes. *Emory Radiology Resources*, 2020. Accessed: 2024-12-12.
- [19] M. Benamor, L. Ollivier, H. Brisse, G. Moulin-Romsee, V. Servois, and S. Neuenschwander. Pet/ct imaging: what radiologists need to know. *Cancer Imaging: The Official Publication of the International Cancer Imaging Society*, 7 Spec No A(Special issue A):S95–S99, 2007.
- [20] A. Arnone, R. Laudicella, F. Caobelli, P. Guglielmo, M. Spallino, E. Abenavoli, A. L. Martini, R. Filice, A. D. Comis, M. Cuzzocrea, F. Linguanti, L. Evangelista, and P. Alongi. Clinical impact of 18f-fdg pet/ct in the diagnostic workup of pancreatic ductal adenocarcinoma: A systematic review. *Diagnostics (Basel, Switzerland)*, 10(12):1042, 2020.
- [21] Daniel Juarez. Comparative efficacy of pet/ct and pet/mr in precision radiotherapy for liver cancer: Advances in dosimetry and tumor delineation. Unpublished manuscript for Radiotherapy class, November 2024.
- [22] Instituto Nacional de Estadística y Geografía (INEGI). Población: Habitantes en México, 2020. Accessed: 2024-12-12.
- [23] Statista Research Department. Density of positron emission tomography (pet) scanners in Mexico from 2010 to 2021, 2021. Accessed: 2024-11-24.
- [24] S. K. Das, M. Miften, S. Zhou, R. K. ten Haken, I. El Naqa, M. Ajlouni, and S. Ghosh. Task group 174 report: Utilization of [18F]-fluorodeoxyglucose positron emission tomography ([18F]-fdg pet) in radiation therapy. *Medical Physics*, 46(1):e1–e15, 2019.
- [25] B. P. Lopez, D. W. Jordan, B. J. Kemp, P. E. Kinahan, C. R. Schmidlein, and O. R. Mawlawi. Pet/ct acceptance testing and quality assurance: Executive summary of aapm task group 126 report. *Medical Physics*, 48(2):e31–e35, 2020.
- [26] R. Seifert, P. Sandach, D. Kersting, W. P. Fendler, B. Hadaschik, K. Herrmann, J. J. Sunderland, and J. H. Pollard. Repeatability of [68Ga]-psma-hbed-cc pet/ct-derived total molecular tumor volume. *Journal of Nuclear Medicine*, 63(5):746–753, 2022.
- [27] John J. Sunderland. Nuclear medicine's age of enlightenment: 2012 to ??, October 2024. Seminar presented at the University of Iowa Health Care, October 2024.
- [28] J. J. Sunderland, S. A. Graves, D. M. York, C. A. Mundt, and T. B. Bartel. Multicenter evaluation of frequency and impact of activity infiltration in pet imaging, including microscale modeling of skin-absorbed dose. *Journal of Nuclear Medicine*, 64(7):1095–1101, 2023.

- [29] L. Zheng, H. Xing, F. Li, and L. Huo. Focal autoimmune pancreatitis mimicking pancreatic cancer on fdg pet/ct imaging. *Clinical Nuclear Medicine*, 43(1):57–59, 2018.
- [30] M. Deng, Y. Chen, and L. Cai. Comparison of [68Ga]-fapi and [18F]-fdg pet/ct in the imaging of pancreatic cancer with liver metastases. *Clinical Nuclear Medicine*, 46(7):589–591, 2021.
- [31] Z. Zhang, S. Guo, C. Zuo, and C. Cheng. A case of pancreatic cancer with rare cutaneous and muscle metastases on [18F]-fdg pet/ct imaging. *Clinical Nuclear Medicine*, 48(8):692–693, 2023.